Industry Briefs: Mar. 5, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Company News

Galapagos has received EUR 3.5 million ($4.59 million) in milestone payments in its osteoarthritis alliance with Servier. Read More

JHP Pharmaceuticals has added a second product to its previously announced multiyear contract manufacturing agreement with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent. Read More

Lonza and Eclipse Therapeutics have formed a development and manufacturing agreement. Read More

Mylan continues to pursue damages and and its injunction against Sunovion’s Brovana in an ongoing litigation. Mylan believes a federal district court erred in its partial summary judgment decision. Read More

Pfenex and DNA2.0 have formed a collaboration on protein expression technology. Read More

People News

Albany Molecular Research (AMRI) has named Tom McGrath as director of quality for aseptic services, and Chris Phillips has been appointed to the role of senior director of operations, at AMRI’s Burlington, Massachusetts site. Read More

Alkermes has appointed Mark Stejbach as chief commercial officer. Read More

AstraZeneca has announced the retirement of Louis Schweitzer from the board as chairman and as a director, effective Sept. 1, 2012. Read More

Novartis has named Brian McNamara division head of Novartis OTC. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here